CD34 and myeloproliferative neoplasm: Therefore, GLS inhibitors can improve the therapeutic effects of the JAK2 inhibitor Ruxolitinib by enhancing its inhibitory effect against CD34(+) and growth of cells with mutated JAK2 in patients with MPN (198).